-
Mashup Score: 0Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
#Tirzepatide weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2. I guess that they will focus first on diabetologists then they will observe that it will be prescribed by …cardiologists as #GLP1RA🤔. Errare humanum est… https://t.co/NciD1WH2tl
-
-
Mashup Score: 0
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Expert Picks, Latest HeadlinesTweet-
Powerful data https://t.co/VjU5znz8rV
-
-
Mashup Score: 0U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Hem/Oncs, Latest HeadlinesTweet-
FDA broadens indication for abemaciclib in high risk early ER+/HER2- breast cancer: No need to use Ki67 anymore. Approved for: - 4 or more nodes - 1-3 nodes with tumor >5cm or grade 3. #BCSM @OncoAlert https://t.co/RjN84En3Y2
-
-
Mashup Score: 13U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Hem/Oncs, Latest HeadlinesTweet-
Remember when everyone was freaking out about ki67 and what it all means? That was fun. 😵💫 It all just got easier! #EasyButton 🔴 FDA Broadens Indication for Verzenio® (abemaciclib) in HR+ Node-Positive, High Risk Early Breast Cancer #bcsm #OncoAlert https://t.co/S0d4M8yqev
-
Just Out🚨 @US_FDA 🇺🇸approves expanded indication for abemaciclib in combo w/ ET for adj tax of HR+ HER2- node-positive, early #BreastCancer at a high risk of recurrence. Label expansion is supported by four-year data from Phase 3️⃣monarchE🦋 @OncoAlert https://t.co/3EsPzpezLg https://t.co/o1AZHiAMk8
-
-
Mashup Score: 0U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Hem/Oncs, Latest HeadlinesTweet-
FDA broadens label for adjuvant abemaciclib, removing Ki67 score for patient selection! Great news, and makes sense given benefit seen irrespective of Ki67 in monarchE @OncoAlert #bcsm https://t.co/7XRNT0HV5V
-
@US_FDA broadens indication for #abemaciclib in #HR+ #bcsm! @SarahCannonDocs https://t.co/VlouDIzSR8
-
-
Mashup Score: 5Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Endocrinology, Latest HeadlinesTweet-
Great news for people with #InsulinDependency! Insulin maker Eli Lilly has capped the out-of-pocket price of insulin at $35. See the press release from Eli Lilly with the link below: https://t.co/grh0TKxf3w https://t.co/xLVURAjVXv
-
-
Mashup Score: 3Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: General Medicine News, Latest HeadlinesTweet-
Lilly cuts insulin prices 70% and caps out-of-pocket costs at $35/month, https://t.co/IucypO3sfb
-
-
Mashup Score: 7Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Hem/Oncs, Latest HeadlinesTweet-
Here is a link to the @LillyPad Press Release with all the details. https://t.co/MjbJ3JvHsN https://t.co/b7o0MGikBu
-
-
Mashup Score: 1
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @NedPagliarulo: $LLY Mounjaro sales of $280M in the fourth quarter: https://t.co/suYkxCRMak Co. says drug has a nearly 22% share of th…
-
@ProfRobHoward @MadhavThambiset @MemoryDoc @dmrind @pxrobbo @gregggonsalves @seb_walsh @metapredict @LogarithmicDis @DrTFromKC @nvillain_alz @JosephTherr @PhilAlz @CorriveauNick @RenegadeSynapse @dcweisman @DavidJonesBrain @ChuckGartland1 @eturnermd1 @kateeeemily @AlbertoEspay @StefanoSensi14 @VincentPlanche @ayton_scott @reshmagar @KarlHerrup @GiovanniFrisoni @macesari @geoperry @samgandy @Gill_Livingston @Kariem_Ezzat @andrea_sturchio @AndaloussiLab @rkhamsi @r_merrick @schrag_matthew @kathy_y_liu @naomikresge @prof @WesselsAlette @LonSchneiderMD @LillyPad ’s Alzheimer’s therapy Donanemab slowed patients’ rate of cognitive decline, data show https://t.co/1vG8schEiU via @matthewherper & @adamfeuerstein